Vitiligo is the most common depigmenting disorder worldwide, with over 1-2% of population being affected by it. The onset of Vitiligo occurs mostly in people between 10 to 30 years of age. Though Vitiligo is not a terminal illness, the disfigurement caused by the disease has profound effect on the quality of life of the patient, as they have to live with it throughout their life. It is a cause of immense psychological torment, with patients feeling isolated and depressed. This disease is of major concern in India, where it is considered as a social stigma, due to its confusion with leprosy. The problem is equally large in other countries, with the disease affecting both personal and professional lives of patients globally.
Vitiligo is an unmet medical need and there is a desperate need to define reliable treatments for managing this disorder.
Vitiligo: Scientific Facts
Ahammune, therefore, is focused on development of molecules that function locally at the site of lesion, resolving the disease without side effects.
Key Facts about Vitiligo Market
Vitiligo cure is an unmet medical need and an international requirement. Therefore there is an urgent need to find a solution. This condition has a huge market potential of $2.7 billion. With a dedicated patient base, Vitiligo therapeutics market is growing at a CAGR of 8.8% (Research and Markets- Vitiligo Therapeutics - Pipeline Assessment and Market Forecasts to 2019).
With a dedicated program of Vitiligo therapy and animal models that faithfully replicate human disease, Ahammune is striving to fulfill this lacuna in resolving the disease. The Company’s compounds are specifically designed towards Vitiligo therapy. Our strategy of using topical small molecules improves drug absorption in skin and decreases the chances of systemic side effects. Our program aims to set paradigms in treating dermatological autoimmune diseases involving localized remission strategies.